{
  "pmcid": "4281162",
  "sha256": "839fbe253a30e09ccaee7c3b2de4ef03f02326240a8bef231ac47b99855e034a",
  "timestamp_utc": "2025-11-09T22:41:52.357749+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.7163133640553,
    "reading_ease": 12.11534916696209,
    "word_count": 217
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of CMV pp65 mRNA-Loaded Dendritic Cell Vaccination"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This randomised controlled trial included four CMV-seronegative healthy volunteers and three allogeneic HSCT recipients"
      },
      "Participants": {
        "score": 2,
        "evidence": "four CMV-seronegative healthy volunteers and three allogeneic HSCT recipients at Antwerp University Hospital"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received four weekly intradermal DC vaccines prepared from a single leukapheresis"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the safety, feasibility, and immunogenicity of CMV pp65 mRNA-loaded autologous monocyte-derived dendritic cells (DC) as a vaccine"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the induction of CMV-specific T-cell responses, assessed one month post-vaccination"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "randomisation details were not specified"
      },
      "Blinding": {
        "score": 0,
        "evidence": "The trial was not blinded"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "four CMV-seronegative healthy volunteers and three allogeneic HSCT recipients"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "four of six efficacy-evaluable subjects"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Three of four healthy volunteers showed de novo CMV-specific T-cell responses without serious adverse events"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included transient local redness and mild swelling at the injection site, with no serious events reported in healthy subjects"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided"
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided"
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}